COMMUNIQUÉS West-GlobeNewswire

ImmuCell Announces Onboarding of New CEO and Related Management Changes
04/11/2025
PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
04/11/2025
Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2 [...]
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
04/11/2025
FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of November 1, 2025 [...]
Ceribell Reports Third Quarter 2025 Financial Results
04/11/2025
SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
04/11/2025
Delivered quarterly XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial [...]
Sight Sciences to Present at Two Upcoming Investor Conferences
04/11/2025
MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Progress Update on BioPorto’s Adult Clinical Study
04/11/2025
November 4, 2025 Announcement no. 21 Progress Update on BioPorto’s Adult Clinical Study Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced [...]
Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025
04/11/2025
November 4, 2025 Announcement no. 22 Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” [...]
Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs
04/11/2025
November 4, 2025 Announcement no. 23 Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“ [...]
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2025
04/11/2025
SAN RAMON, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report fourth quarter and full year 2025 financial results on Thursday, [...]
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
04/11/2025
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./ [...]
Anaptys Announces Participation in November Investor Conferences
04/11/2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president [...]
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
04/11/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/11/2025
SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation
04/11/2025
Châtillon, France, le 4 novembre (22 :30 CET) 2025 DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market [...]
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
04/11/2025
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2 nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP [...]
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
04/11/2025
Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed $80 [...]
Precipio Announces Q3-2025 Shareholder Update Call
04/11/2025
Conference Call to be held on November 17th, 2025 at 5:00 PM EST NEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q3-2025 [...]
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
04/11/2025
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the [...]

Pages